TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04807400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Support
Description: Regular telephone based behavioural support programme delivered throughout the study period, as measured by point of care testing device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background lipid lowering therapy
Description: lipid-lowering therapy (such as a statin and/or ezetimibe) as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background lipid lowering therapy
Description: lipid-lowering therapy (such as a statin and/or ezetimibe) as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background lipid lowering therapy
Description: lipid-lowering therapy (such as a statin and/or ezetimibe) as background therapy
Study: NCT05110495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab
Description: The study IMP is xentuzumab, a humanised IgG1 monoclonal antibody that neutralises the IGF ligands to inhibit activation of IGF-1R and INSR-A, suppressing IGF-mediated proliferation, invasion and therapy resistance
Study: NCT05023187

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CON
Description: A 8-week active control intervention consisting of 2 sessions (\~45 minutes each) of cognitive stimulation exercises and a group session for each week (24 sessions in total) during which the various cognitive domains are deepened and the exercises carried out during the week are reviewed all together.~The online control intervention has been specifically designed to increase the cognitive involvement of the subjects and to replicate the condition of exposure to social dynamics.
Study: NCT04699708

Intervention type: DEVICE
Intervention: Carbon dioxide monitoring
Description: Blinded recording of CO2 during preterm resuscitation.
Study: NCT05888246

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetocardiogram
Description: Magnetocardiogram consists of acquisition and control system (including software) and detection part. Acquisition and control system mainly includes: cabinet, display, host, sensor. The detection part mainly includes: inspection bed, array sensor support frame, magnetic shielding equipment.
Study: NCT06633627

Intervention type: OTHER
Intervention: Recording of brain activity using electroencephalography (EEG)
Description: Electroencephalography (EEG) responses to sensitivity stimuli applied to the teeth in patients with and without dentine hypersensitivity will be compared

Intervention type: OTHER
Intervention: Recording of brain activity using electroencephalography (EEG)
Description: Electroencephalography (EEG) responses to sensitivity stimuli applied to the teeth in patients with and without dentine hypersensitivity will be compared
Study: NCT04977479

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)
Description: mRNA vaccine for the prevention of COVID-19. Single dose (0.3mL) via IM.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)
Description: mRNA vaccine for the prevention of COVID-19. Single dose (0.3mL) via IM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 Vaccine (Comirnaty)
Description: mRNA vaccine for the prevention of COVID-19. Single dose (0.3mL) via IM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Commercially available sterile, preservative-free 0.9% Sodium Chloride Injection, USP. Volume to match active vaccine controlling for and delivered as a single dose via IM.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available sterile, preservative-free 0.9% Sodium Chloride Injection, USP. Volume to match active vaccine controlling for and delivered as a single dose via IM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Description: mRNA vaccine booster bivalent (Original and Omicron BA.4/BA.5) for the prevention of COVID-19. Single dose (0.3mL) via IM.
Study: NCT05718895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-022
Description: Dose Escalation Phase:~A treatment cycle of ATG-022 will be defined as 21 days. Dosing will begin at 0.3 mg/kg once every 3 weeks (Q3W) with 1 subject ,the following dose cohorts (0.9, 1.8, 2.4, 3.0, and 3.6 mg/kg Q3W) will require at least 3 and up to 6 evaluable subjects by using dose escalation plan of 3+3 design.
Study: NCT06200545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP eligibility assessment
Description: PrEP eligibility assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PrEP eligibility assessment
Description: PrEP eligibility assessment

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid HIV antibody testing prior to provision and/or refill of PrEP
Description: Rapid HIV antibody testing prior to provision and/or refill of PrEP

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rapid HIV antibody testing prior to provision and/or refill of PrEP
Description: Rapid HIV antibody testing prior to provision and/or refill of PrEP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines
Description: PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines
Description: PrEP follow-up with a PrEP nurse in accordance with contemporary PrEP guidelines

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of barriers and facilitators to ongoing PrEP use
Description: Evaluation of barriers and facilitators to ongoing PrEP use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement
Description: Point of contact STI testing to inform counseling regarding ongoing PrEP care engagement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tracing for any missed PrEP visits
Description: Tracing for any missed PrEP visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period
Description: Offering a PrEP restart kit for cisgender men who choose to discontinue PrEP during the follow-up period
Study: NCT05052476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bactecal® D Liquid
Description: The patients will be randomized into two arms, A and B, in function of the intervention dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bactecal® D Liquid
Description: The patients will be randomized into two arms, A and B, in function of the intervention dose
Study: NCT06582498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active intervention
Description: This group will receive a pamphlet with diet and lifestyle recommendations for cancer survivors at randomization (2nd visit). Furthermore, they will be offered 3 individual sessions with health professionals (oncological dietitian, sports therapist, and oncological psychologist) and 3 group sessions with the same professionals. The duration of the individual visits is expected to be 45-60 minutes approximately, and group sessions will be planned for 1.5h duration approximately.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity intervention
Description: This group will receive a pamphlet with diet and lifestyle recommendations for cancer survivor at randomization (2nd visit). These recommendations are all based on information from the World Cancer Research Fund, the American Institute for Cancer Research, and the American Cancer Society.
Study: NCT06581783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone plus NAC
Description: Drug simethicone plus N acetylcysteine will be given before endoscopy with different time intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone plus NAC
Description: Drug simethicone plus N acetylcysteine will be given before endoscopy with different time intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simethicone plus NAC
Description: Drug simethicone plus N acetylcysteine will be given before endoscopy with different time intervals
Study: NCT05986695

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alert
Description: Interruptive alert. The prototype alert is in the form of a chart note with evidence-based practice guidelines that will actively display in the clinician's list of daily alerts (like an inbox) that must be cleared daily. It is interruptive because can only be dismissed from the clinician's inbox list after signing the note

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alert
Description: Interruptive alert. The prototype alert is in the form of a chart note with evidence-based practice guidelines that will actively display in the clinician's list of daily alerts (like an inbox) that must be cleared daily. It is interruptive because can only be dismissed from the clinician's inbox list after signing the note

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer comparison report
Description: Clinicians will receive an email describing their recent SGLT2 and MRA prescribing performance relative to their peers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer comparison report
Description: Clinicians will receive an email describing their recent SGLT2 and MRA prescribing performance relative to their peers.
Study: NCT06418516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule-sponge
Description: The capsule-sponge is a minimally-invasive sampling device consisting of a polyurethane sponge compressed in a cellophane capsule attached to a string. When swallowed, the capsule dissolves in the stomach, releasing the cell collection sponge that expands to 3 cm in diameter. Next, a nurse or qualified medical technician retrieves the sponge by pulling back on the string and retracting it through the mouth. During extraction, the rough texture on the surface of the sponge collects epithelial cells in the cardia and along the entire length of the esophagus.
Study: NCT04625244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video assisted home therapy
Description: Subjects will follow along with prerecorded therapy videos.
Study: NCT05019950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIM-1324
Description: Once daily oral tablet
Study: NCT06333535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot massage
Description: foot massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: abdominal massage
Description: abdominal massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot and abdominal massage
Description: foot and abdominal massage
Study: NCT05601986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy and Rehabilitation Program
Description: The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase: Progressive relaxation. Stretching phase: Stretching exercises for the muscles of the gastrocnemius, hamstrings, hip flexors, hip adductors Strengthening phase: Isometric strengthening exercises for the tibialis anterior, quadriceps, hip extensors, and hip abductors muscles.~Balance training phase: Two legs, one leg, balance with eyes open and eyes closed.~Weight-bearing phase: Weight transfer to the front, back, and sides using the balance board.

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy and Rehabilitation Program
Description: The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase: Progressive relaxation. Stretching phase: Stretching exercises for the muscles of the gastrocnemius, hamstrings, hip flexors, hip adductors Strengthening phase: Isometric strengthening exercises for the tibialis anterior, quadriceps, hip extensors, and hip abductors muscles.~Balance training phase: Two legs, one leg, balance with eyes open and eyes closed.~Weight-bearing phase: Weight transfer to the front, back, and sides using the balance board.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional Motor Imagery Training to Physiotherapy and Rehabilitation Program
Description: The program will be held for 8 weeks, 2 days a week, with 40-minute sessions. Relaxation phase, Stretching phase, Strengthening phase,Balance training phase and Weight-bearing phase. Additional to the Physiotherapy and Rehabilitation Program, the Additional Motor Imagery Training program will be carried out for 8 weeks, 2 days a week, in addition to the 40-minute physiotherapy and rehabilitation program, accompanied by 25-30 minutes of supervision. It will be conducted by the researcher on two non-consecutive days of the week, by making appropriate appointments for the participants. During the program, participants will be asked to be in a quiet room. Sessions will consist of 4 consecutive phases: video watching, relaxation, motor imagery, and return to the environment.
Study: NCT06275594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Byfavo
Description: For induction and maintenance of sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: For induction and maintenance of sedation
Study: NCT04896320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tucatinib is a highly selective, oral, reversibly Her2 small molecule tyrosine kinase inhibitor (TKI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tucatinib is a highly selective, oral, reversibly Her2 small molecule tyrosine kinase inhibitor (TKI).
Study: NCT06397352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ShotBlocker®
Description: All children underwent a standard procedure. The standard procedure involved taking the child into the vaccination room, providing information about the vaccination procedure, introducing the researcher, and obtaining consent. The STAI-S was completed immediately before the vaccination. Children were assigned to groups as specified in the randomization procedure. The vaccination of children was performed by an experienced nurse working in the unit where the study was conducted to control for practitioner-related factors.It is positioned onto the skin before an injection is made. After positioning the ShotBlocker® and ensuring that the contacts were in contact with the children's skin, the injection was made through the central hole by the nurse. The ShotBlocker® was cleaned with 70% alcohol before use on another child.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buzzy® Group
Description: All children underwent a standard procedure. The standard procedure involved taking the child into the vaccination room, providing information about the vaccination procedure, introducing the researcher, and obtaining consent. The STAI-S was completed immediately before the vaccination. Children were assigned to groups as specified in the randomization procedure. The vaccination of children was performed by an experienced nurse working in the unit where the study was conducted to control for practitioner-related factors. Vibrations started 30 seconds before the procedure and continued until it was completed. The device was cleaned with 70% alcohol before use on another child
Study: NCT06113133

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of oxygen uptake
Description: oxygen uptake is obtained during a maximal exercise test
Study: NCT05351268

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioactive seed brachytherapy
Description: The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing coplanar template includes information on the path of the implantation needle, the needle path can be controlled accurately which can make the operation more accurate.
Study: NCT05773820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJB001
Description: Dose Escalation:~Accelerated titration (the first two dose groups) and BOIN combination (the subsequent dose group) were used for dose escalation.~Dose Expansion:~Based on the previous data, 1 to 2 doses were selected to further evaluate the initial efficacy, safety, tolerability and pharmacokinetic characteristics to confirm RP2D.~Cohort Expansion:~The preliminary plan of cohort expansion phase uses the Simon two-stage optimal method to expand 2 to 3 cohorts.
Study: NCT04877470

Intervention type: OTHER
Intervention: Consultation at spine-centre
Description: All patients who visited the spine-centre for the first time in 2019 are included in this group.
Study: NCT06063577

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stratafix suture
Description: Stratafix symmetric suture

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care suture
Description: Standard of care suture
Study: NCT04777695

Intervention type: OTHER
Intervention: Decibel Monitor
Description: Placement of a TeckPro data logging sound decibel meter at all patient bed-spaces to measure concurrent sound levels 24 hours per day, over a one (1) month period. Peak and mean sound levels per hour will be collected by the decibel monitor. Sound collected every 5 minutes will be logged by the decibel monitor and downloaded onto manufacturer software daily; data will then be imported into Microsoft Excel for further data analysis.
Study: NCT06064474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High ventilation breathwork with retention (HVBR)
Description: Intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo HVBR
Description: Placebo
Study: NCT05490589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EQUIPE Program
Description: EQUIPE is a manualised group community-based parent education programme. Groups consist of 15 parents who meet with one or two trained group leaders for weekly 2-hour sessions over 10 weeks.~This program promotes skill development in parents, strengthens relationships with children, increases cooperation, and helps solve problems in the home.
Study: NCT06275594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: For induction and maintenance of sedation
Study: NCT05019950

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily oral tablet
Study: NCT06075992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: An experimental application will not be made to premature babies in this group.
Study: NCT05295147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palmar Grasp Reflex Stimulation
Description: The palmar grasp reflex is an involuntary flexion-adduction movement involving the hands and fingers.
Study: NCT06512896

Intervention type: OTHER
Group type: OTHER
Intervention: FOLactis
Description: Evaluate the safety,tolerability, efficacy of intraluminal injection of FOLactis combined with chemotherapy, target therapy, and immunotherapy
Study: NCT06030492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: packing placental site with hydrogen peroxide soaked towels
Description: Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done Irrigation of the placental bed with 100 ml 3% hydrogen peroxide , followed by packing with a towel highly soaked hydrogen peroxide solution (Pozitif Kimya, İstanbul, Turkey) , freshly prepared by a 50% dilution with a normal saline solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: Skin is incised either midline or Pfannenstiel incision according to clinical situation , bladder dissection will be done , uterus will be incised by transverse lower segment incision , followed by delivery of the baby.~Uterine massage , ecbolics \& a trial for delivery of the placenta will be done.~Packing the placental bed with a towel soaked with normal Saline solution
Study: NCT05796115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procalcitonin/Presepsin guided antibiotic prophylaxis for EOS
Description: Infants will receive antibiotic prophylaxis for EOS on the basis of Procalcitonin and Presepsin values measured within the first 3 hours of life.
Study: NCT05877495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Education Intervention
Description: A 14-session training created by the researchers by examining the literature and various guides. This training includes about, prevention food waste with kitchen activities, food safety, food security and waste control. The content of the intervention will be loaded soon.
Study: NCT05709470

Intervention type: OTHER
Intervention: No-intervention
Description: Observational cross-sectional study design with no intervention

Intervention type: OTHER
Intervention: No-intervention
Description: Observational cross-sectional study design with no intervention
Study: NCT04914091

Intervention type: OTHER
Intervention: Semi-structured interviews and self-administered questionnaires
Description: Interviews and questionnaires will be performed before administration of CAR-T cells, 3 month after and 6 month after, and will last 60 minutes each time. Semi-structured interview using pre-established questionnaires will be completed with a hospital pharmacist, concerning the patient's perception of his family, socio-professional environment, his knowledge of his illness and his treatment, the consumption of prescribed drugs outside the hospital, self-medication, complementary alternative therapies including herbal medicine. Seven self-administered questionnaires will be completed, concerning quality of life, Assessment of Cancer Treatment-Lymphoma, Beliefs about Medicines, Brief Illness Perception, satisfaction with medication, perceived social support scale, and on Health Literacy.
Study: NCT05102747

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated SRT (stereotactic radiotherapy)
Description: 3\*10Gy over 1 week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Historical single-dose SRS (stereotactic radiosurgery)
Description: 20 to 25Gy/1 fraction
Study: NCT05329259

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: One dose of 13vPnC (0.5mL) will be administered intramuscularly.
Study: NCT05796115

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic prophylaxis for EOS
Description: Infants will receive antibiotic prophylaxis for EOS.